GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Total Assets

Genetic Technologies (Genetic Technologies) Total Assets : $5.67 Mil (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Total Assets?

Genetic Technologies's Total Assets for the quarter that ended in Dec. 2023 was $5.67 Mil.

During the past 12 months, Genetic Technologies's average Total Assets Growth Rate was -55.50% per year. During the past 3 years, the average Total Assets Growth Rate was 70.30% per year. During the past 5 years, the average Total Assets Growth Rate was 68.80% per year. During the past 10 years, the average Total Assets Growth Rate was 2.40% per year.

During the past 13 years, Genetic Technologies's highest 3-Year average Total Assets Growth Rate was 100.10%. The lowest was -34.30%. And the median was -4.90%.

Total Assets is connected with ROA %. Genetic Technologies's annualized ROA % for the quarter that ended in Dec. 2023 was 0.00%. Total Assets is also linked to Revenue through Asset Turnover. Genetic Technologies's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.


Genetic Technologies Total Assets Historical Data

The historical data trend for Genetic Technologies's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Total Assets Chart

Genetic Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.27 10.79 17.56 14.62 9.97

Genetic Technologies Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.59 - 9.97 - 5.67

Genetic Technologies Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Genetic Technologies's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets=Total Equity (A: Jun. 2023 )+Total Liabilities (A: Jun. 2023 )
=7.492+2.479
=9.97

Genetic Technologies's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=3.221+2.446
=5.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Technologies  (NAS:GENE) Total Assets Explanation

Total Assets is connected with ROA %.

Genetic Technologies's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (0+5.667)/ 1 )
=0/5.667
=0.00 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Genetic Technologies's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (0+5.667)/ 1 )
=0/5.667
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Genetic Technologies Total Assets Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies (Genetic Technologies) Business Description

Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.